ESTRO 2024 - Abstract Book

S1757

Clinical - Lung

ESTRO 2024

2) Cella L, D'Avino V, Palma G et al. Modeling the risk of radiation-induced lung fibrosis: Irradiated heart tissue is as important as irradiated lung. Radiother Oncol. 2015 Oct;117(1):36-43. doi:10.1016/j.radonc.2015.07.051. Epub 2015 Aug 12. PMID: 26277435. 3) Nix MG, Rowbottom CG, Vivekanandan S et al. Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival- limiting toxicity effects indicates a low α/β ratio. Radiother Oncol. 2020 Feb;143:58-65. doi: 10.1016/j.radonc.2019.07.026.

Acknowledgements This work was supported by the AIRC MFAG ID 27480

2625

Digital Poster

Lung stereotactic body radiotherapy (SBRT) for patients with severe lung function impairment

Alexandra Giraldo, Abraham André Arturo Geng Cahuayme, Blanca Peregrín, Mónica Ramos, Xavier Maldonado

Vall d`Hebron University Hospital, Radiation Oncology, Barcelona, Spain

Purpose/Objective:

To evaluate clinical outcomes after SBRT in a cohort of early stage non-small cell lung cancer (NSCLC) or pulmonary metastases in chronic obstructive pulmonary disease (COPD) patients with forced expiratory volume in the first second predicted (FEV1) ≤ 50%.

Material/Methods:

A retrospective single-center was performed to analyze clinical outcomes and toxicities in COPD patients with severe lung dysfunction treated with SBRT from 1st June 2015 to 31st October 2022. Patients included were ≥18 years of age and KPS>70, with primary lung cancer or lung metastases smaller than 5cm. All patients included in the analysis had a spirometry with FEV1 predicted value ≤ 50% within 3 months prior to initiation of SABR. Patients were excluded if they had a history of concurrent chemotherapy or immunotherapy, prior thoracic radiotherapy, small cell lung cancer histology, interstitial lung disease, or lung transplantation. Clinical follow-up was performed 1, 3, and 6 months after SBRT and every 6 months thereafter in all patients. Treatment toxicity was registered according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. In addition, considering that patients with COPD and poor pulmonary function tests are often admitted to the emergency department because of exacerbation of their disease, respiratory infections during the first year after SBRT were reviewed in all patients.

Results:

Thirty-four patients (forty locations) were enrolled for analysis. Median follow-up was 2.9 years. Table 1 shows clinical and demographic characteristics. Median age was 73.5 years (range, 65.6 - 80.1). Before the start of radiotherapy, the median FEV1 was 38% (range, 28.2 - 50.0) and 0.94 L (range, 0.83 - 1.05), and the median FVC was